Jenburkt Pharmaceuticals Limited (BOM:524731)
1,042.30
-13.80 (-1.31%)
At close: Feb 12, 2026
Jenburkt Pharmaceuticals Revenue
Jenburkt Pharmaceuticals had revenue of 430.24M INR in the quarter ending December 31, 2025, with 16.62% growth. This brings the company's revenue in the last twelve months to 1.65B, up 10.48% year-over-year. In the fiscal year ending March 31, 2025, Jenburkt Pharmaceuticals had annual revenue of 1.52B with 6.85% growth.
Revenue (ttm)
1.65B
Revenue Growth
+10.48%
P/S Ratio
2.82
Revenue / Employee
2.12M
Employees
779
Market Cap
4.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.52B | 97.25M | 6.85% |
| Mar 31, 2024 | 1.42B | 52.17M | 3.82% |
| Mar 31, 2023 | 1.37B | 127.69M | 10.30% |
| Mar 31, 2022 | 1.24B | 146.86M | 13.44% |
| Mar 31, 2021 | 1.09B | -95.97M | -8.07% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sudarshan Pharma Industries | 6.44B |
| Kopran | 6.20B |
| ZIM Laboratories | 3.66B |
| Albert David | 3.16B |
| Amanta Healthcare | 2.83B |
| Accent Microcell | 2.78B |
| Kilitch Drugs (India) | 2.09B |
| Everest Organics | 1.89B |